Table 3.

Response and survival data in each tumor type in phase 1b (N = 176)

	Sugemalimab monotherapy			Sugemalimab in combination with chemotherapy
	CC/GBC (N = 29)	HCC (≥ 2L) (N = 19)	MSI-H/dMMR (≥ 2L) (N = 21)	GAC/GEJAC (1L) (N = 29)	ESCC (1L) (N = 37)	Non-squamous NSCLC (1L) (N = 21)	Squamous NSCLC (1L) (N = 20)
PR*, n (%)	2 (6.9)	2 (10.5)	8 (38.1)	18 (62.1)	25 (67.6)	10 (47.6)	15 (75.0)
SD, n (%)	9 (31.0)	1 (5.3)	3 (14.3)	6 (20.7)	8 (21.6)	9 (42.9)	4 (20.0)
PD, n (%)	14 (48.3)	12 (63.2)	8 (38.1)	3 (10.3)	2 (5.4)	2 (9.5)	0
NA, n (%)	4 (13.8)	4 (21.1)	2 (9.5)	2 (6.9)	2 (5.4)	0	1 (5.0)
ORR, %	6.9	10.5	38.1	62.1	67.6	47.6	75.0
DCR, %	37.9	15.8	52.4	82.8	89.2	90.5	95.0
Median DoR, months	5.4	4.5	13.8	11.3	–	8.7	6.4
(95% CI)	(2.8, 8.0)	(2.2, 6.9)	(2.1, –)	(3.9, –)	(6.2, –)	(1.8, –)	(6.2, –)
Median PFS, months	2.2	2.1	4.1	8.3	9.0	6.5	8.4
(95% CI)	(2.0, 4.2)	(1.4, 2.1)	(2.0, 15.8)	(4.8, 13.3)	(4.4, –)	(4.4, 11.7)	(8.2, –)
Median OS, months	11.0	7.1	–	17.0	–	–	–
(95% CI)	(6.4, 16.1)	(2.3, 18.7)	(14.6, –)	(12.1, –)	(9.7, –)	(10.4, –)	(13.9, –)

 ≥ 2L, second-line or after; 1L, first-line; CC/GBC, cholangiocarcinoma or gallbladder carcinoma; HCC, hepatocellular carcinoma; MSI-H/dMMR, solid tumors with MSI-H/dMMR phenotype; GAC/GEJAC, gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; ESCC, esophageal squamous cell carcinoma; NSCLC, non-small cell lung cancer. PR, partial response; SD, stable disease; PD, progressive disease; NA, patient do not have any assessment post-baseline; ORR, objective response rate; DCR, disease control rate; DoR, duration of response; PFS, progression-free survival; OS, overall survival

^*Response was assessed in accordance with the Response Evaluation Criteria in Solid Tumors version 1.1. Responses were unconfirmed